Perivascular epithelioid cell tumour: the decisions you may face

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

1. Between Limb-salvage surgery and endoprosthetic reconstruction and Active surveillance, which do you recommend for me, and what about my case would make you choose differently?
   Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. For my situation (localised), which of the standard options do you recommend and why?
   Why: Guideline options include: Complete resection; surveillance for tumours with malignant features; no proven adjuvant therapy.

Add these to your appointment list, or take the full question set for this cancer.

• AMPECTPhase 2NCT02494570202134 peopleevidence 51
  Tests Sirolimus protein-bound particles
  Advanced malignant PEComa: nab-sirolimus (albumin-bound sirolimus)

  Objective response 39% (independent review), durable, enriched in TSC2-mutant tumours; FDA approval November 2021.

  Objective response rate (independent review) (percent): Nab-sirolimus 39 (n=31) · source

1. Between Sirolimus protein-bound particles, Everolimus and Temsirolimus, which do you recommend for me, and what about my case would make you choose differently?
   Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. How closely do I match the people in AMPECT, and does that change what the results mean for me?
   Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
4. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
5. For my situation (advanced malignant pecoma), which of the standard options do you recommend and why?
   Why: Guideline options include: Nab-sirolimus (AMPECT; FDA approved 2021); oral sirolimus, everolimus or temsirolimus as alternatives; check TSC status.
6. Am I a candidate for Sirolimus protein-bound particles, Everolimus, Temsirolimus, and what side effects should I expect?
   Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
7. How do the results of AMPECT apply to someone like me?
   Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

• Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)Phase 2NCT05103358120 peopleevidence 30
  A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

  No headline result recorded yet.

1. Between Doxorubicin and Gemcitabine, which do you recommend for me, and what about my case would make you choose differently?
   Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. How closely do I match the people in Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1), and does that change what the results mean for me?
   Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
4. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
5. For my situation (after mtor inhibitor), which of the standard options do you recommend and why?
   Why: Guideline options include: Anthracycline- or gemcitabine-based chemotherapy has modest activity; trials of mTOR-based combinations; PRECISION 1 for TSC-altered tumours.
6. Am I a candidate for Doxorubicin, Gemcitabine, and what side effects should I expect?
   Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
7. How do the results of Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) apply to someone like me?
   Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.